LL-191

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameLL-191
Drug Alias NameLL-191
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Epidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCapella Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCapella Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A